Lithium and pregnancy

Abstract

The lifetime prevalence of bipolar affective disorder is approximately 1% in both men and women (Reiger et al , 1998). In women the illness is most prevalent in the child-bearing years (Robins et al , 1984). While lithium for the treatment of bipolar disorder is a cornerstone of modern psychopharmacology (Llewellyn et al , 1998), there are inherent problems in treating this sizeable subgroup of patients, as lithium presents small, but significant, risks to a potential foetus. It is also becoming increasingly obvious that serious mental illness poses a risk to the unborn child. This paper reviews those risks, presents a protocol in algorithmic form for dealing with the prescription of lithium in pregnancy and discusses practical issues pertaining to dosage and lithium monitoring.